Glaukos Corporation $GKOS Stake Boosted by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS raised its stake in Glaukos Corporation (NYSE:GKOS) by 7.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 11,700 shares of the medical instruments supplier’s stock after buying an additional 800 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Glaukos were worth $1,208,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its stake in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 158 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 159 shares during the last quarter. Park Place Capital Corp lifted its stake in Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 162 shares during the last quarter. Bayforest Capital Ltd bought a new stake in Glaukos in the first quarter valued at $141,000. Finally, Revisor Wealth Management LLC bought a new stake in Glaukos in the second quarter valued at $204,000. 99.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group raised their target price on Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group initiated coverage on shares of Glaukos in a research note on Wednesday, October 1st. They set a “buy” rating and a $103.00 price objective on the stock. Mizuho set a $130.00 price objective on shares of Glaukos in a research note on Thursday, July 31st. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research note on Thursday, July 31st. Finally, Zacks Research cut shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $116.92.

Glaukos Trading Up 2.7%

Shares of GKOS opened at $85.29 on Wednesday. The business’s 50-day moving average price is $87.81 and its 200 day moving average price is $92.43. The stock has a market capitalization of $4.89 billion, a P/E ratio of -51.69 and a beta of 0.76. Glaukos Corporation has a 1-year low of $77.10 and a 1-year high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. The firm had revenue of $124.12 million for the quarter, compared to analysts’ expectations of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.Glaukos’s revenue was up 29.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. Analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.